Articles
Choosing the best metabolic treatment in elderly patients with coronary heart disease
V.Yu. Lyshnevska, MD, M.S. Papuha, V.A. Yelnykova, Institute of Gerontology of the National Academy of Medical Sciences of Ukraine, Kyiv
Notwithstanding the advances achieved in the prevention and treatment of coronary heart disease (CHD) in recent years, optimization of its treatment remains among the most relevant problems of contemporary cardiology. The high medical and social relevance of this problem is associated with conditions that aggravate the course of CHD, such as myocardial infarction, heart failure (HF) and sudden coronary death, the incidence of which considerably exceeds the expected value calculated taking into account the implementation of current medical treatment regimens. That is why, there is a continuing search for therapeutic options to increase the life expectancy and the quality of life in patients with CHD, aimed mainly at optimizing the metabolic processes in the myocardium.
EFFICACY OF THIOTRIAZOLIN IN COMBINATION WITH THE STANDARD OF CARE FOR THE TREATMENT OF CORONARY HEART DISEASE (Results of a double-blind randomized placebo-controlled study)
V.Z. NETIAZHENKO, T.I. MALCHEVSKA
O.O. Bohomolets National Medical University
The treatment of coronary heart disease (CHD) has long been addressed from the perspective of cardiac hemodynamics improvement. It is known that the pathogenetically targeted action of conventional medicines is aimed at reducing the myocardial oxygen demand or increasing the oxygen supply to heart muscle cells. Medicinal products that influence the hemodynamic parameters are effective in preventing angina attacks but provide virtually no protection against ischemic changes to the myocardial cells.
Сlinical efficacy and tolerability of Тhiotriazolin in patients with unstable angina
Ye.P. SVISHCHENKO, L.V. BEZRODNAYA
National Research Center “M.D. Strazhesko Institute of Cardiology” of the National Academy of Medical Sciences of Ukraine
V.P. SHPAK, A.H. DUBCHAK
“Kyiv Regional Cardiology Dispensary”, Municipal Institution of the Kyiv Regional Council
Mechanism of energotropic and antioxidant action of Thiotriazolin
I.F. Belenichev, Head of the Pharmacology and Medical Formulation Department; I.A. Mazur, Head of the Pharmaceutical Chemistry Department; M.A. Voloshyn, MD, Head of the Human Anatomy Department, Zaporizhia State Medical University, Farmatron R&D and Production Association, Zaporizhia; N.O. Horchakova, MD; I.S. Chekman, MD, Head of the Pharmacology Department, O.O. Bohomolets National Medical University, Kyiv
Efficacy of Thiotriazolin® versus Meldonium in patients with class II or class III stable angina. Results of a prospective, randomized, open-label, parallel-group, comparative study
Yu.M. Sirenko, MD, A.D. Radchenko, MD, K.V. Mikheieva, O.L. Rekovets,
National Research Center “M.D. Strazhesko Institute of Cardiology” of the NAMS of Ukraine, P.N. Babych, The State Expert Center, Kyiv
CHOOSING A METABOLIC THERAPY IN PATIENTS WITH CORONARY HEART DISEASE
Vasyl Zakharovych NETIAZHENKO
Editor-in-Chief, Associate Member of the AMS of Ukraine, MD, Head of the Internal Medicine Propedeutics Department No. 1 at O.O. Bohomolets National Medical University, Honored Science and Technology Worker of Ukraine
T.I. MALCHEVSKA, H.I. MISHANYCH, T.D. ZALEVSKA, A.H. MASHKEVYCH, O.O. Bohomolets National Medical University, Kyiv
Copyright © 2023, Arterium Corporation
